Open Access This article is distributed under the terms of the Cr

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and

the source are credited. References Anderson D, Glibert P, Burkholder J (2002) Harmful algal blooms and eutrophication: nutrient sources, composition, and consequences. Estuaries Coasts 25(4):704–726. doi:10.​1007/​bf02804901 CrossRef Babin M, Therriault J, Legendre L, Nieke B, Reuter R, Condal A (1995) Relationship between the maximum quantum yield of Small molecule library cell assay carbon fixation and the minimum quantum yield of chlorophyll a in vivo fluorescence in the Gulf of St. Lawrence. Limnol Oceanogr 40(5):956–968CrossRef Beutler M, Wiltshire KH, Meyer B, Moldaenke C, Luring C, Meyerhofer M, Hansen UP, Dau H (2002) A fluorometric method for the differentiation of algal populations in vivo and in situ. Photosynth Res 72(1):39–53. doi:10.​1023/​A:​1016026607048 PubMedCrossRef Beutler M, Wiltshire KH, Arp M, Kruse J, Reineke C, Moldaenke C, Hansen UP (2003) A reduced model of the fluorescence from the cyanobacterial photosynthetic apparatus designed for the in situ detection of cyanobacteria. Biochim

Biophys Acta-Bioenerg 1604:33–46. doi:10.​1016/​S0005-2728(03)00022-7 CrossRef Beutler M, Wiltshire KH, Reineke C, Hansen UP (2004) Algorithms and practical fluorescence models of the photosynthetic apparatus of red cyanobacteria and cryptophyta designed for the fluorescence detection of red cyanobacteria and cryptophytes. Montelukast Sodium Aquat Microb Ecol 35(2):115–129. doi:10.​3354/​ame035115 CrossRef Bidigare CYT387 clinical trial RR, Ondrusek ME, Morrow JH, Kiefer DA (1990) In vivo absorption properties of algal pigments. SPIE Proc Ocean Opt X 1302:290–302 Biggins J, Bruce D (1989) Regulation of excitation-energy transfer in organisms containing phycobilins. Photosynth Res 20(1):1–34. doi:10.​1007/​BF00028620 CrossRef Campbell D, Bruce D, Carpenter C, Gustafsson P, Öquist G (1996) Two forms of the photosystem II D1

protein alter energy dissipation and state transitions in the cyanobacterium Synechococcus sp. PCC 7942. Photosynth Res 47(2):131–144. doi:10.​1007/​BF00016176 CrossRef Campbell D, Hurry V, Clarke AK, Gustafsson P, Öquist G (1998) Chlorophyll fluorescence analysis of cyanobacterial photosynthesis and acclimation. Microbiol Mol Biol Rev 62(3):667–683PubMed Ernst A, Becker S, Wollenzien UIA, Postius C (2003) Ecosystem-dependent adaptive radiations of picocyanobacteria inferred from 16S rRNA and ITS-1 sequence analysis. Microbiol 149(1):217–228. doi:10.​1099/​mic.​0.​25475-0 CrossRef Ficek D, Kaczmarek S, Ston-Egiert J, Wozniak B, Majchrowski R, Dera J (2004) Spectra of light absorption by phytoplankton pigments in the Baltic; conclusions to be drawn from a Gaussian analysis of empirical data.


Untagged Selleckchem Androgen Receptor Antagonist cis-complemented sepD::escU(N262A) and sepD::escU(P263A) strains (expressing the respective escU allele from the chromosome) were generated by allelic exchange and were found to produce the same secretion profile as the respective plasmid complemented strains (Figure 4A). Immunoblotting with monoclonal anti-Tir antibodies revealed that Tir secretion occurred at variable levels

when EscU or EscU variants were expressed although for EscU(N262A), a novel lower molecular weight polypeptide was detected with anti-Tir antibodies (Figure 4B). This novel polypeptide species was consistently absent from ΔsepDΔescU/pJLT21 or pJLT23 and the parent ΔsepD strain. Figure 4 EscU auto-cleavage is required for efficient and stable effector secretion in an EPEC Δ sepD genetic background. (A) Left: Trans-complementation of ΔsepDΔescU with pJLT21 restored secretion Tubastatin A mouse of effectors to ΔsepD

levels while ΔsepDΔescU/pJLT22 did not restore normal effector secretion. ΔsepDΔescU/pJLT23 secreted a protein with an apparent molecular mass similar to Tir (asterisk). The dominant effector proteins are labelled and have been previously identified using mass spectrometry analyses [35]. Purified BSA was added to collected secreted fractions and served to aid in protein precipitation. Right: genomic integration of mutant escU alleles (cis-complementation, single copy) produces the same secretion phenotypes as the plasmid trans-complemented escU strains. Total secreted proteins were visualized by Coomassie G-250 staining. (B) Secreted protein preparations were analyzed by immunoblot with anti-Tir antibodies. Due

to the abundance of secreted Tir in ΔsepD and ΔsepDΔescU/pJLT21, (see Coomassie stain in panel A), only these samples were diluted 20 fold for immunoblotting purposes while the others were undiluted. A ΔsepDΔtir strain Orotidine 5′-phosphate decarboxylase (undiluted) was included to show the specificity of the anti-Tir antibodies. Lower molecular weight protein species are therefore Tir breakdown products that were consistently observed and recognized by the anti-Tir antibodies. A novel Tir polypeptide, indicated by an arrow, was exclusively detected in the lane containing secreted proteins derived from ΔsepDΔescU/pJLT22. CesT membrane localization is altered in the absence of EscU auto-cleavage In a previous report, we have demonstrated that the multicargo type III chaperone CesT mediates effector ‘docking’ at the inner membrane in an EscN-dependent manner [39]. CesT is also required for Tir stability in the EPEC cytoplasm [46, 47] and mediates efficient secretion of at least 9 type III effectors [39]. It has also been demonstrated that CesT contributes to effector translocation [42, 43].

From then on, several articles about HFE mutations and HCC have b

From then on, several articles about HFE mutations and HCC have been published. learn more We selected nine eligible studies including 1102 cases and 3766 controls to conduct an updated meta-analysis. Because HH is more frequent in northern European populations, the studies on HFE gene mutations and HCC are mainly come from European ethnicities. In this meta-analysis, eight studies were come from Europe and one from Africa. So, the analysis results may be mainly applicable to European populations and it warrants to be studied in other ethnicities. In this meta-analysis, the frequency of C282Y YY homozygotes was 0.42%

(16/3766), and the frequency of CY heterozygotes was 9.32% (351/3766) in all control subjects. The genotype distribution was consistent with the dbSNP data. H63D genotype distribution was 2.66% (60/2258) and 23.78% (537/2258) for DD homozygotes and HD heterozygotes in controls, respectively. As to C282Y, the ORs of allele contrast (Y vs. C) in the six studies [8,

10–12, 15, 31] were larger than 1.0. Among the six studies, four studies [8, 10–12] reported a significant association between HCC and the C282Y polymorphism (ORs > 1.0, 95%CIs did not include 1.0). Because the frequency of the homozygous mutation of C282Y is very low, and a large proportion of C282Y homozygotes had been diagnosed with HH and received treatment, such as venesection before developing LC or HCC, the conclusion OSI-027 in vitro that Sitaxentan YY homozygotes increased HCC risk may have little clinical value. Thus, we only explored the dominant model and allele contrast in this meta-analysis. This meta-analysis proved that C282Y mutation was associated with HCC in European populations, especially in alcoholic LC patients but not in viral LC patients. This result is consistent

with the results of three previous studies [8, 15, 38], and it may implicate that the hepatocarcinogenesis of alcoholic LC and viral LC is different and warrants further study. Some studies explored the role of gender in the influence of the relationship between HFE gene and HCC [10, 14, 34] and found that C282Y homozygotes YY mutation increased the risk of HCC in male patients. One English study [10] reported that male C282Y homozygotes were more likely to be diagnosed with HCC (OR = 14, 95%CI: 5-37), and the penetrance of the C282Y homozygous genotype, with respect to HCC, was between 1.31% and 2.1% for males and zero for females. Another study [36] reported that C282Y homozygote males had a relative risk (RR) of about 23 for HCC occurrence, and the penetrance, with respect to HCC, was 5.56%. As there were few studies that provided concrete gender subgroup genotype values, we could not make a pooled analysis. From the pooled genotype data, we could assess the statistical power under various subgroup analyses using PS software [27].

Pointing and Belnap (2014) review regional-scale impacts arising

Pointing and Belnap (2014) review regional-scale impacts arising from the disturbance of dryland soils and the biocrust communities living on them. They identify the causes of disturbance, emphasize the mobilization of dust to the atmosphere as a major driver of these impacts, and discuss the negative environmental consequences for terrestrial and marine ecosystems, including potential threats to biotic communities and

human health. Major efforts of biocrust researchers have traditionally been devoted to understanding their role in controlling soil and wind erosion (e.g. Eldridge and Greene 1994; Belnap and Gillette 1998; Bowker et al. 2008), and to study the factors influencing the hydrological behavior of biocrusts (e.g. Belnap 2006; Eldridge et al. 2010; Rodríguez-Caballero selleck chemical et al. 2013). Two articles in this issue deal with these topics. Zhao et al. (2014) evaluate the response of biocrusts of different successional stages to raindrop erosivity Citarinostat price in the northern Shaanxi province of China. Despite the large number of studies on this topic, research separating the multiple mechanisms of erosion control by biocrusts has been limited. These authors

found that biocrusts dramatically improved the resistance of the soil to erosion, and that the biocrust effect varied with both biocrust species composition and the successional stage. Their results suggest that the influence

of biocrusts can be incorporated into erosion models. The microstructure of the soil underneath biocrusts is one of the factors affecting their hydrological behavior (Belnap 2006). Felde et al. (2014) investigated the change of the pore system of three different successional stages of biocrusts in the NW Negev Desert (Israel) to describe the influence of the soil microstructure of biocrusts on water redistribution. They reported that the pore system undergoes significant the changes during crust succession; total porosity, as well as the pore sizes significantly increased from cyanobacteria- to lichen- and moss-dominated biocrusts, and the pore geometry changed from tortuous to straight pore shapes throughout this succession. The authors conclude that the influences of the structural properties of biocrusts must be considered to a much greater extent when investigating their hydrological behavior. While diversity assessments of above-ground biocrust constituents, like mosses, liverworts, and lichens, have been conducted for many years (e.g. Crespo 1973; Büdel et al. 2009; Buschardt 1979; Eldridge and Tozer 1996; Gutiérrez and Casares 1994; Rogers 2006), researchers have recently started to explore the diversity of microorganisms associated to biocrusts (e.g. Bates et al.

This study aimed at comparing the differences of the microbiota a

This study aimed at comparing the differences of the microbiota and metabolome between CD children under GFD (treated celiac disease, T-CD) and non-celiac children (healthy control, HC). The intestinal and faecal microbiota was characterized by culture-independent and -dependent methods whereas metabolomic studies were carried out using gas-chromatography mass spectrometry/solid-phase microextraction BI 10773 nmr (GC-MS/SPME) and 1H nuclear magnetic resonance (NMR) spectroscopy. Results Molecular analysis of the bacterial community of duodenal biopsies and faecal samples The dominant microbiota and specific subgroups (Bifidobacteria and Lactobacillus)

from stool samples and from duodenal biopsies (mucus and mucosa associated bacteria) were analyzed by PCR (Polymerase chain reaction)-DGGE (denaturing gradient gel electrophoresis). Universal primers targeting V6-V8 regions of the 16S rRNA gene were used. Eubacterial AG-881 datasheet profiles from PCR-DGGE analysis of duodenal biopsies of treated celiac disease (T-CD) children showed high richness

with two to eight well resolved and strong bands (Figure 1A). Only the electrophoretic profile of 19 T-CD duodenal biopsy contained one band. Profiles of non-celiac children (HC) had only one to three strong bands. Banding patterns were processed using the Bionumerics software. Pearson correlation coefficients ranged from 4.6 to 99.5%. Except for two duodenal biopsies (33 and 34 HC) which showed high similarity to T-CD samples, all HC banding patterns were grouped together with 98.2% similarity coefficient. The major part of the T-CD samples were grouped together at 95% of the similarity. Overall, DGGE profiles of the PCR amplicons obtained with primers Lac1 and Lac2 had two strong, common and well-resolved bands, and a few bands with low intensity (Figure 1B). High similarity was found among samples belonging to T-CD and HC groups. Most of the T-CD and HC duodenal biopsies were grouped together at ca. 90% of similarity and all samples at 72.9%. Sequencing of the DGGE bands

revealed the common presence of L. plantarum (band a). Although Lac1 and Lac2 primers were commonly used to detect Lactobacillus species [9, 24, 25], human DNA (band these b) was also found. Finally, no PCR amplicons were found by using three different sets of primers targeting the Bifidobacteria group. This suggested that Bifidobacteria were probably absent from duodenal biopsies of both T-CD and HC. Figure 1 Clustering of denaturing gradient gel electrophoresis (DGGE) profiles of biopsies from thirty-four children (1-34). Universal V6-V8 (A) and Lac1/Lac2 Lactobacillus group (B) primers were used. Clustering was carried out using the unweighted pair-group method with the arithmetic average (UPGMA) based on the Pearson correlation coefficient.

Table 3 Distribution of

Table 3 Distribution of Dinaciclib nmr elective cancer operations performed by subspecialty surgical oncologists (non-general

surgeons) at Victoria Hospital, before and after the implementation of ACCESS (pre- and post-ACCESS, respectively) Variable Pre-ACCESS, n (%) Post-ACCESS, n (%) Change, n (%) P value Number of cases, n 1685 1624 -61 (-4) – Number of cases by priority level, n (%)       <0.0001   P2 187 (11) 95 (6) -92 (-49)     P3 1027 (61) 768 (47) -259 (-25)     P4 471 (28) 761 (47) +290 (+62)   No. of cases exceeding wait-time targets by priority, n (%)       0.39   P2 120 (64) 61 (64) -59 (-49)     P3 485 (47) 297 (39) -188 (-39)     P4 122 (26) 118 (16) -4 (-3)   Median wait-times by priority, days (range)       0.52   P2 19 (1–215) 17 (1–55) -2 (-10)     P3 27 (0–274) 23 (0–108) -4 (-14)     P4 66 (0–246) 41 (0–207) -25 (-37)   Type of cancer, n (%)       < 0.0001   Gastric 21 (1) 10 (0.6) -11 (-52)     Endocrine 238 (14) 172

(11) -66 (-28)     Genitourinary (excluding prostate) 228 (14) 230 (14) +2 (+1)     Gynecological 350 (21) 284 (17) -66 (-19)     Head and neck (excluding thyroid) 154 (9) 276 (17) +122 (+79)     Lung 168 (10) 194 (12) +26 (+15)     Lymph 2 (0.1) 3 (0.2) +1 (+50) Danusertib     Peripheral nervous system 1 (0.1) 3 (0.2) +2 (+200)     Prostate 132 (8) 105 (6) -27 (-20)     Skin carcinoma1 8 (0.5) 7 (0.4) -1 (-13)     Skin melanoma 49 (3) 30 (2) -19 (-39)   1Includes basal and squamous cell carcinoma. Discussion As ACS continues to flourish around the world, an increasing number of studies have emphasized the benefits of this care model for patients with general surgical emergencies [2, 5, 8, 15–18]. Surgical departments, however, have historically been expensive to run because of the costly equipment, support staff, as well as the specialized nursing and medical staff required [19]. The operating

room, therefore, is viewed as a necessary but expensive liability in the financially-constrained Thalidomide Canadian healthcare system. Consequently, funding for the implementation of surgical programs such as ACS services often requires the reallocation of pre-existing operating room resources. Prior to the implementation of ACCESS at our institution, there was no structured system for performing emergency general surgery cases during the daytime. Emergency patients would usually have their operation in the evening or night, after the completion of the daytime elective caseload, or they would have their operation during the daytime at the expense of cancelling one or more elective cases. Alternatively, patients would stay in the hospital—sometimes for days— before a surgeon was able to perform an operation during his elective schedule. The goal of ACCESS, therefore, was to provide more timely access to the OR for emergency general surgery, while decreasing the amount of expensive “after-hours” surgeries, all the while without increasing the overall general surgery operating volume.

Conclusions Complicated intra-abdominal infections are an importa

Conclusions Complicated intra-abdominal infections are an important cause of morbidity and are frequently associated with a poor prognosis. Despite advances in diagnosis, surgery, antimicrobial therapy mortality associated

with complicated intra-abdominal infections remains still unacceptably high. Early adequate source control remains the cornerstone of intra-abdominal infection management. Early control of the septic source can be achieved either by nonoperative or operative means. Timing and adequacy of source control is the most important issue in the management of intra-abdominal infections, because an inadequate and late operation may have a negative effect on outcome. Recent advances in interventional and more aggressive techniques are debated and are not validated by limited prospective trials. Concomitant

adequate empiric antimicrobial mTOR inhibitor therapy further influences patients morbidity and mortality. Inappropriate antibiotic therapy of intra-abdominal infections may result in poor patient outcome and the selection of an appropriate agent is a real challenge because of the emerging resistance of target organisms to commonly prescribed antibiotics. References 1. Menichetti F, Sganga G: Definition and classification of intra-abdominal infections. J Chemother 2009,21(Suppl 1):3–4.PubMed 2. Malangoni MA, Inui T: Peritonitis – the Western experience. World J Emerg Surg 2006, 1:25.PubMed 3. Schoeffel U, Jacobs E, Ruf G, Mierswa F, von Specht BU, Farthmann EH: Intraperitoneal micro-organisms and the severity of peritonitis. Eur J Surg 1995, Tanespimycin concentration 161:501–508.PubMed 4. Wacha H, Hau T, Dittmer R, Ohmann C: Risk factors associated with intraabdominal infections: a prospective multicentre study. Peritonitis Study Group.

Langenbecks Arch Surg 1999, 384:24–32.PubMed 5. Mulier S, Penninckx f, Verwaest C, Filez L, Aerts R, Fieuws S, Lauwers P: Factors affecting mortality in generalized postoperative peritonitis: multivariate analysis in 96 patients. World J Surg 2003, 27:379–384.PubMed 6. Pieracci FM, Barie PS: Management of severe sepsis of abdominal origin. Scand J Surg 2007,96(3):184–196.PubMed 3-mercaptopyruvate sulfurtransferase 7. Mulari K, Leppäniemi A: Severe secondary peritonitis following gastrointestinal tract perforation. Scand J Surg 2004,93(3):204–208.PubMed 8. Horiuchi A, Watanabe Y, Doi T, Sato K, Yukumi S, Yoshida M, Yamamoto Y, Sugishita H, Kawachi K: Evaluation of prognostic factors and scoring system in colonic perforation. World J Gastroenterol 2007,13(23):3228–3231.PubMed 9. Evans HL, Raymond DP, Pelletier SJ, Crabtree TD, Pruett TL, Sawyer KG: Tertiary peritonitis (recurrent diffuse or localized disease) is not an independent predictor of mortality in surgical patients with intra-abdominal infection. Surg Infect 2001, 2:255–265. 10. McLauchlan GJ, Anderson ID, Grant IS, Fearon KCH: Outcome of patients with abdominal sepsis treated in an intensive care unit. Br J Surg 1995, 82:524–529.PubMed 11.

Construction of ifp complement in pBAD33 plasmid The ifp gene inc

Construction of ifp complement in pBAD33 plasmid The ifp gene including native promoter was amplified by PCR using specific primers INTPROM3 + INTPROM4 (Table 2). After ligation into pGEM-T Easy vector (Promega) the construct was transformed into Ipatasertib XL2-Blue E. coli (Stratagene,

La Jolla, USA). The construct was screened by PCR and sequenced, before the ifp gene with promoter was digested from the pGEM-T Easy vector with KpnI and SphI and purified by gel extraction using a Gen Elute purification kit (Sigma). This insert was cloned into a pBAD33 plasmid [34], also digested with KpnI and SphI and transformed into TOP10 E. coli (Invitrogen). These colonies were again screened by PCR and by digestion with EcoRV to confirm the correct selleck insert and orientation within the pBAD33 vector. IPΔIFP cells were made competent by washing 3 times in 10 ml ice cold H2O and electroporated with pBAD33ifp

(pIFP) plasmid to generate an ifp mutant with a complemented ifp gene (IPΔIFPpIFP). These were screened by PCR and were DNA sequenced again to confirm the presence of the correct complemented gene. Plasmid cured strains Wild type, defined mutants and ifp complemented mutant strains lacking the pYV plasmid were generated by culturing strains overnight at 37°C the selecting for white colonies on CRMOX plates [31]. Loss of pYV was verified by PCR and repeated screening on CRMOX. Adhesion and invasion of HEp-2 cells HEp-2 cells were cultured overnight at 37°C 5% CO2 on coverslips in 24-well plates at 2 × 105 cells/well in RVX-208 1 ml tissue culture medium. The 10 ml LB broth cultures of IP32953 wild type (IPWT), defined mutants (IPΔIFP, IPΔINV, IPΔIFPΔINV) and mutant with complemented ifp (IPΔIFPpIFP), were incubated at 37°C for 14 hours with appropriate antibiotics and 2.5 mM CaCl2. The cells were washed 3 times with 1 ml PBS and then, at a multiplicity of infection (MOI) of 70:1, incubated for 1 hour with 1 ml of bacterial culture in MEM media at 37°C, 5% CO2. Inoculum was plated on LB agar to determine

number of colony forming units (cfu). The cells were washed 5 times with 1 ml PBS and then fixed with 2% paraformaldehyde (w/v) for 45 minutes at 4°C, before being washed again 5 times with 1 ml PBS. The coverslips were incubated with a 1:500 dilution of anti-Yersinia pseudotuberculosis antibody (Abcam, Cambridge, UK) in PBS for 45 minutes at room temperature. The coverslips were washed with PBS then incubated with a 1:1000 dilution of anti-rabbit IgG Alexafluor 488 (green) (Invitrogen) in PBS for 45 minutes at room temperature. After washing with PBS the cells were permeabilised with 0.1% Triton X100-PBS (v/v) for 20 minutes at room temperature. The coverslips were washed with PBS and incubated with 1:500 dilution of anti-Y. pseudotuberculosis antibody (Abcam) in PBS for 45 minutes at room temperature, before being washed again with PBS.

Calcif Tissue Int 76:176–186PubMedCrossRef 243

Tilyard M

Calcif Tissue Int 76:176–186PubMedCrossRef 243.

Tilyard MW, Spears GF, Thomson J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357–362PubMedCrossRef Belinostat in vitro 244. Gallagher JC, Rapuri PB, Smith LM (2007) An age-related decrease in creatinine clearance is associated with an increase in number of falls in untreated women but not in women receiving calcitriol treatment. J Clin Endocrinol Metab 92:51–58PubMedCrossRef 245. McCloskey E, Selby P, Davies M et al (2004) Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 19:728–736PubMedCrossRef 246. McCloskey EV, Beneton M, Charlesworth D et al (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 22:135–141PubMedCrossRef 247. Boonen S, Van Meirhaeghe J, Bastian L, Cummings SR, Ranstam

J, Tillman JB, Eastell R, Talmadge K, Wardlaw D (2011) Balloon kyphoplasty for the treatment of acute vertebral compression fractures: 2-year results from a randomized trial. J Bone Miner Res 26:1627–1637PubMedCrossRef Semaxanib solubility dmso 248. Lekkerkerker F, Kanis JA, Alsayed N et al (2007) Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 18:1311–1317PubMedCrossRef 249. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Brookhart MA (2005) Compliance with osteoporosis medications. Arch Intern Med 165:2414–2419PubMedCrossRef 250. Hiligsmann M, Gathon HJ, Bruyere O, Ethgen O, Rabenda V, Reginster JY (2010) Prostatic acid phosphatase Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health 13:394–401PubMedCrossRef

251. Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811–818PubMedCrossRef 252. Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14:571–581PubMedCrossRef 253. Strom O, Borgstrom F, Kanis JA, Jonsson B (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20:23–34PubMedCrossRef 254. Kanis JA, Cooper C, Hiligsmann M, Rabenda V, Reginster JY, Rizzoli R (2011) Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int 22:2565–2573PubMedCrossRef 255. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008PubMedCrossRef 256.

J biomed opt 2009,14(3):030509 PubMedCrossRef 9 Wang Y, Zhang Z,

J biomed opt 2009,14(3):030509.PubMedCrossRef 9. Wang Y, Zhang Z, Garbow JR, Rowland DJ, Lubet RA, Sit D, Law F, You M: Chemoprevention of lung squamous cell carcinoma in mice by a mixture of Chinese herbs. Cancer Prev Res (Phila) 2009,2(7):634–640.CrossRef 10. Rodt T, Luepke M, Boehm C, von Falck C, Stamm G, Borlak J, Seifert H, Galanski M: Phantom GSK2879552 and cadaver measurements of dose and dose distribution in micro-CT of the chest in mice. Acta Radiol 2011,52(1):75–80.PubMedCrossRef

11. Rodt T, von Falck C, Halter R, Ringe K, Shin HO, Galanski M, Borlak J: In vivo microCT quantification of lung tumor growth in SPC-raf transgenic mice. Front biosci: j virtual library 2009, 14:1939–1944.CrossRef 12. Kirsch DG, Grimm J, Guimaraes AR, Wojtkiewicz GR, Perez BA, Santiago PM, Anthony NK, Forbes T, Doppke K, Weissleder R, et al.: Imaging primary lung cancers in mice to study radiation biology. Int j radiat oncol, biol, Compound Library phys 2010,76(4):973–977.CrossRef 13. Fushiki H, Kanoh-Azuma T, Katoh M, Kawabata K, Jiang J, Tsuchiya N, Satow A, Tamai Y, Hayakawa Y: Quantification of mouse pulmonary cancer models by microcomputed tomography imaging. Cancer sci 2009,100(8):1544–1549.PubMedCrossRef 14. Cody DD, Nelson CL, Bradley WM, Wislez M, Juroske D, Price RE, Zhou X, Bekele BN, Kurie JM: Murine lung tumor measurement using respiratory-gated micro-computed tomography.

Investig radiol 2005,40(5):263–269.CrossRef Quinapyramine 15. Ramasamy K, Dwyer-Nield LD, Serkova NJ, Hasebroock KM, Tyagi A, Raina K, Singh RP, Malkinson AM, Agarwal R: Silibinin prevents lung tumorigenesis in wild-type but not in iNOS-/- mice: potential of real-time micro-CT in lung cancer chemoprevention studies. Clin cancer res: an official J Am Assoc Cancer Res 2011,17(4):753–761.CrossRef 16. Namati E, Thiesse J, Sieren JC, Ross A, Hoffman EA, McLennan G: Longitudinal

assessment of lung cancer progression in the mouse using in vivo micro-CT imaging. Med phys 2010,37(9):4793–4805.PubMedCrossRef 17. Hori Y, Takasuka N, Mutoh M, Kitahashi T, Kojima S, Imaida K, Suzuki M, Kohara K, Yamamoto S, Moriyama N, et al.: Periodic analysis of urethane-induced pulmonary tumors in living A/J mice by respiration-gated X-ray microcomputed tomography. Cancer sci 2008,99(9):1774–1777.PubMed 18. De Clerck NM, Meurrens K, Weiler H, Van Dyck D, Van Houtte G, Terpstra P, Postnov AA: High-resolution X-ray microtomography for the detection of lung tumors in living mice. Neoplasia 2004,6(4):374–379.PubMedCrossRef 19. Bartling SH, Dinkel J, Stiller W, Grasruck M, Madisch I, Kauczor HU, Semmler W, Gupta R, Kiessling F: Intrinsic respiratory gating in small-animal CT. Eur radiol 2008,18(7):1375–1384.PubMedCrossRef 20. Bartling SH, Stiller W, Grasruck M, Schmidt B, Peschke P, Semmler W, Kiessling F: Retrospective motion gating in small animal CT of mice and rats.